MDA 19 (Standard)

MDA 19 (Standard) is the analytical standard of MDA 19. This product is intended for research and analytical applications. MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a Ki of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity[1][2].

Product Specifications

CAS Number

[1048973-47-2]

Product Name Alternative

BZO-HEXOXIZID (Standard)

UNSPSC

12352005

Target

Cannabinoid Receptor; Reference Standards

Type

Reference Standards

Related Pathways

GPCR/G Protein; Neuronal Signaling; Others

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/mda-19-standard.html

Smiles

O=C(C1=CC=CC=C1)N/N=C2C(N(C3=C\2C=CC=C3)CCCCCC)=O

Molecular Formula

C21H23N3O2

Molecular Weight

349.43

References & Citations

[1]Diaz, Philippe; Xu, Jijun; Astruc-Diaz, Fanny et al. Design and Synthesis of a Novel Series of N-Alkyl Isatin Acylhydrazone Derivatives that Act as Selective Cannabinoid Receptor 2 Agonists for the Treatment of Neuropathic Pain. Journal of Medicinal Chemistry (2008), 51 (16), 4932-4947.|[2]Xu JJ, Diaz P, Astruc-Diaz F et al. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth Analg. 2010 Jul;111 (1) :99-109.